BioGeneric Pharma   Report issue

For profit Phase 3
Founded: Cairo Egypt (1995)
Status: No NME R&D (1995)

Organization Overview

First Clinical Trial
2010
NCT01327729
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

interferon alpha-2b (Intron-A) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1